MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

MicrobioTx Launches Gut Function Test (GFT) for Easy, Affordable Gut Health Profiling

Roche to Present Over 40 Abstracts on Blood Disorders at 66th ASH Annual Meeting, Showcasing Advances in Lymphoma Treatments

Hamad Medical Corporation Hosts 3rd Precision Medicine Conference on AI and Genomics Integration

Caris Life Sciences Receives FDA Approval for Groundbreaking MI Cancer Seek™ Diagnostic Assay for Precision Oncology

IWG Proposes New Clinical-Biological Definition for Diagnosing Alzheimer’s Disease

Inify Laboratories and Karolinska Institutet's ProMort Team Partner to Transform Prostate Cancer Diagnostics with AI

UK Government and Oxford Nanopore Forge Partnership to Advance Genomics in the NHS, Enhancing Patient Care and Biosecurity

HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Home
/
update
/
details

Celyad Oncology Appoints Matt Kane as Chief Executive Officer

NextEdge Admin

17 Sep 2024

2 min 23 sec

Celyad Oncology has appointed Matt Kane as its new Chief Executive Officer, effective October 1st, 2024. Kane brings over 20 years of experience in leadership roles within biotechnology, including a pioneering background in genome editing and CAR T-cell therapies. He has led the development of the first gene insertion therapeutic cleared for clinical evaluation and directed the clinical testing of several allogeneic CAR T-cell therapies. Throughout his career, Kane has demonstrated both scientific and business acumen, successfully raising over $500M in equity financings and forming partnerships valued at over $4B.

Kane most recently served as CEO of Tune Therapeutics, where he spearheaded the development of a lead epigenetic editing therapeutic candidate. He previously co-founded Precision BioSciences in 2006 and served as its CEO until 2021, where he oversaw the company’s IPO and directed four allogeneic CAR T therapies into human clinical studies.

Hilde Windels, Chair of the Board at Celyad, expressed confidence in Kane’s ability to help the company achieve its ambitious goals, citing his expertise in the CAR T space and strong background in research, development, and intellectual property monetization. Kane expressed enthusiasm for joining Celyad and advancing its innovative CAR T-cell therapy pipeline.

Celyad Oncology is a biotechnology company focused on developing next-generation CAR T-cell therapies, utilizing proprietary technology platforms and intellectual property. Its mission is to harness these technologies to create transformative cancer treatments that have the potential to revolutionize the CAR T-cell therapy landscape.